ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADMA ADMA Biologics

Market Closed 05-17 16:00:00 EDT

9.21

+0.15

+1.66%

盘后9.20

-0.01-0.11%

19:36 EDT

High9.31	Low8.91	Vol3.63M
Open9.07	D1 Closing9.06	Amplitude4.42%
Mkt Cap2.13B	Tradable Cap2.09B	Total Shares231.81M
T/O33.39M	T/O Rate1.60%	Tradable Shares227.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics","latestPrice":9.21,"timestamp":1715976000000,"preClose":9.06,"halted":0,"volume":3628993,"hourTrading":{"tag":"盘后","latestPrice":9.2,"preClose":9.21,"latestTime":"19:36 EDT","volume":46190,"amount":425477.809,"timestamp":1715988982608},"delay":0,"floatShares":227199972,"shares":231809197,"eps":-0.016144,"marketStatus":"Market Closed","change":0.15,"latestTime":"05-17 16:00:00 EDT","open":9.07,"high":9.31,"low":8.91,"amount":33391856.109123,"amplitude":0.04415,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.016144,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716192000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.06,"preHourTrading":{"tag":"盘前","latestPrice":9.12,"preClose":9.06,"latestTime":"09:29 EDT","volume":4560,"amount":41564.86512,"timestamp":1715952599999},"postHourTrading":{"tag":"盘后","latestPrice":9.2,"preClose":9.21,"latestTime":"19:36 EDT","volume":46190,"amount":425477.809,"timestamp":1715988982608},"volumeRatio":0.699639},"requestUrl":"/m/hq/s/ADMA/tweets","defaultTab":"tweets","newsList":[{"id":"2435676442","title":"Zacks.com featured highlights ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education","url":"https://stock-news.laohu8.com/highlight/detail?id=2435676442","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435676442?lang=en_us&edition=fundamental","pubTime":"2024-05-16 18:13","pubTimestamp":1715854380,"startTime":"0","endTime":"0","summary":"Chicago, IL – May 16, 2024 – Stocks in this week’s article are ADMA Biologics Inc. ADMA, Northern Technologies International Corp. NTIC, PlayAGS Inc. AGS, Merchants Bancorp MBIN and Strategic Education Inc. STRA.5 Stocks with Recent Price Strength to Tap May's Rally. The 15-month bull run of U.S. stock markets suffered a surprise setback in April. We believe that April’s meltdown was nothing but a bull market correction, and this time a welcome one, as Wall Street has rebounded in May.The Department of Labor reported that the U.S. economy added 175,000 jobs in April, missing the consensus estimate of 200,000. Job additions in March were revised upward by 12,000 while those in February were revised downward by 34,000. The unemployment rate increased to 3.9% in April, compared with the consensus estimate and March’s data of 3.8%. April marked the highest level since January 2022.However, recent price strength alone cannot create magic. Therefore, other relevant p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rkRlfJUbFheDXif9qCKV2A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/236d157ebb08cbf8ff3dbacf7ce7623b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rkRlfJUbFheDXif9qCKV2A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/236d157ebb08cbf8ff3dbacf7ce7623b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-com-featured-highlights-adma-101300155.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435302686","title":"5 Stocks With Recent Price Strength to Tap May's Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2435302686","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435302686?lang=en_us&edition=fundamental","pubTime":"2024-05-15 20:05","pubTimestamp":1715774700,"startTime":"0","endTime":"0","summary":"The 15-month bull run of U.S. stock markets suffered a surprise setback in April. We believe that April’s meltdown was nothing but a bull market correction, and this time a welcome one, as Wall Street has rebounded in May.The Department of Labor reported that the U.S. economy added 175,000 jobs in April, missing the consensus estimate of 200,000. Job additions in March were revised upward by 12,000 while those in February were revised downward by 34,000. The unemployment rate increased to 3.9% in April, compared with the consensus estimate and March’s data of 3.8%. April marked the highest level since January 2022.Month over month, the average hourly earnings rate dropped to 0.2% in April, compared with the consensus estimate and March’s data of 0.3%. Year over year, the wage rate increased 3.9% in April but came in below the consensus estimate of 4%.The Department of Commerce reported that U.S. GDP grew at a 1.6% annualized rate in first-quarter 2024, well below the consensus estimate","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aePoY5ZOnV7ub408AqQ4QA--~B/aD00MzM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7c4df663699c823ba05ae4b84ac121f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aePoY5ZOnV7ub408AqQ4QA--~B/aD00MzM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7c4df663699c823ba05ae4b84ac121f2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-stocks-recent-price-strength-120500717.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435811576","title":"Adma Biologics Beats Expectations: Analyst Raises Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2435811576","media":"WallStreetZen","top":-1,"share":"https://ttm.financial/m/news/2435811576?lang=en_us&edition=fundamental","pubTime":"2024-05-15 15:08","pubTimestamp":1715756880,"startTime":"0","endTime":"0","summary":"Raymond James's Elliot Wilbur raised their price target on Adma Biologics (NASDAQ: ADMA) by 25% from $8 to $10 on 2024/05/10. The analyst maintained their Strong Buy rating on the stock.Wilbur's posit","market":"us","thumbnail":"https://images.unsplash.com/photo-1576669801775-ff43c5ab079d?crop=entropy&cs=tinysrgb&fit=crop&fm=jpg&ixid=M3w0NDY2OTN8MHwxfHNlYXJjaHw1fHxBZG1hJTIwQmlvbG9naWNzfGVufDB8MHx8fDE3MDkzNTg2ODN8MA&ixlib=rb-4.0.3&q=80&w=260&utm_source=wallstreetzen&utm_medium=referral&utm_campaign=api-credit&h=180","type":0,"news_type":0,"thumbnails":["https://images.unsplash.com/photo-1576669801775-ff43c5ab079d?crop=entropy&cs=tinysrgb&fit=crop&fm=jpg&ixid=M3w0NDY2OTN8MHwxfHNlYXJjaHw1fHxBZG1hJTIwQmlvbG9naWNzfGVufDB8MHx8fDE3MDkzNTg2ODN8MA&ixlib=rb-4.0.3&q=80&w=260&utm_source=wallstreetzen&utm_medium=referral&utm_campaign=api-credit&h=180"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.wallstreetzen.com/news/adma-biologics-beats-expectations-analyst-raises-price-target","is_publish_highlight":false,"gpt_icon":0},{"id":"2435372014","title":"Are Medical Stocks Lagging  ADMA Biologics (ADMA) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2435372014","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435372014?lang=en_us&edition=fundamental","pubTime":"2024-05-13 21:40","pubTimestamp":1715607612,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics  been one of those stocks this year?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adma Biologics is a member of the Medical sector. This group includes 1048 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #1 .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-adma-biologics-134012244.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434605336","title":"Giving ADMA Biologics A Well-Deserved 'Booyah'","url":"https://stock-news.laohu8.com/highlight/detail?id=2434605336","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434605336?lang=en_us&edition=fundamental","pubTime":"2024-05-12 18:00","pubTimestamp":1715508007,"startTime":"0","endTime":"0","summary":"ADMA Biologics reported stellar Q1 results after the bell on Thursday, May 9th, and the stock shot forward by 27% in trading on Friday.The company seems to be executing on all cylinders, and management ratcheted up forward guidance for both FY2024 and FY2025.Can the shares continue to rally after this 'Booyah' quarter?An updated analysis around ADMA Biologics follows in the paragraphs below.Jose Luis Pelaez Inc/DigitalVision via Getty Images ADMA Biologics  reported Q1 results after the bell on Thursday. The company posted stellar results and raised forward guidance. Shareholders were rewarded with a better than 25% rally in the stock on Friday. Can the good times continue?","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/533768557/image_533768557.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/533768557/image_533768557.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4692517-giving-adma-biologics-well-deserved-booyah","is_publish_highlight":false,"gpt_icon":0},{"id":"2434873620","title":"ADMA Biologics First Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2434873620","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2434873620?lang=en_us&edition=fundamental","pubTime":"2024-05-11 21:25","pubTimestamp":1715433959,"startTime":"0","endTime":"0","summary":"NasdaqGM:ADMA Earnings and Revenue Growth May 11th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 6.0%. Earnings per share  also surpassed analyst estimates by 33%.Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.The company's shares are up 29% from a week ago.Every company has them, and we've spotted   1 warning sign for ADMA Biologics   you should know about.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-first-quarter-2024-132559063.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434895775","title":"ADMA Biologics hits 52-week high on Q1 beat, guidance raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2434895775","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434895775?lang=en_us&edition=fundamental","pubTime":"2024-05-11 03:31","pubTimestamp":1715369503,"startTime":"0","endTime":"0","summary":"ADMA Biologics  was a notable gainer among biotechs on Friday, reaching a 52-week high on above-average volumes after the plasma-derived treatment maker topped consensus with its Q1 2024 financials and raised its guidance. Its quarterly beat was driven by a ~44% YoY rise in revenue, which reached $81.9M in Q1, thanks mainly to higher sales of its immunoglobulin products. “ADMA’s commercial success continues to unfold, and during the first quarter of 2024, we surpassed our financial expectations and delivered compounding earnings growth,” CEO Adam Grossman remarked. The company also exceeded forecasts with its earnings as its gross margin improved to ~48% from ~29% in the prior-year period, more than doubling its bottom line to $17.8M on a reported basis.  ADMA Biologics  lifted its 2024 and 2025 revenue guidance to more than $355M and $410M from more than $330M and $380M previously and compared to $333.8M and ~$390.0M in the consensus, respectively.","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499205246/image_499205246.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499205246/image_499205246.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104806-adma-biologics-stock-gains-q1-beat","is_publish_highlight":false,"gpt_icon":0},{"id":"2434816893","title":"ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2434816893","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2434816893?lang=en_us&edition=fundamental","pubTime":"2024-05-11 02:26","pubTimestamp":1715365606,"startTime":"0","endTime":"0","summary":"ADMA Biologics, Inc. beats earnings expectations. Reported EPS is $0.07532, expectations were $0.05. ADMA isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter .Operator: Good afternoon, and welcome to the ADMA Biologics First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 09, 2024. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company’s request and will be available on the company’s website approximately two hours following the end of the call. At this time, I would like to introduce Skyler Bloom, Please go ahead.We specifically disclaim any obligation to update any such statements except as required by the federal securities laws. We refer you to the Disclosure Notice section in our earnings release we issued today in the Risk Factors section of our annual report on Form 10-K for the year ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x1Fu7wr0FD_8Fd_RRzMl0A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/eab076c4e4d80e46ef999cba9561e6cd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x1Fu7wr0FD_8Fd_RRzMl0A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/eab076c4e4d80e46ef999cba9561e6cd"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-inc-nasdaq-adma-182646885.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434670738","title":"ADMA Biologics Inc (ADMA) Surpasses Analyst Revenue and Earnings Forecasts in Q1 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2434670738","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2434670738?lang=en_us&edition=fundamental","pubTime":"2024-05-11 01:25","pubTimestamp":1715361900,"startTime":"0","endTime":"0","summary":"Revenue: Reported $81.9 million, a 44% increase year-over-year, surpassing estimates of $77.28 million.Net Income: Achieved $17.8 million, a significant improvement from a net loss of $6.8 million year-over-year, exceeding estimates of $12.43 million.Adjusted EBITDA: Reached $26.4 million, marking a 970% increase from the previous year.Gross Margin: Improved to 48% in Q1 2024 from 29% in Q1 2023.Future Revenue Guidance: Increased for FY 2024 to over $355 million and for FY 2025 to over $410 million.GuruFocus has detected 5 Warning Sign with ADMA.ADMA has also revised its financial guidance upwards for the fiscal years 2024 and 2025, reflecting confidence in its continued commercial success and operational strategies. For FY 2024, the company now expects total revenue to exceed $355 million and net income to surpass $85 million. For FY 2025, revenue is anticipated to top $410 million wi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qtAnoDEEsPykGhYplrsssw--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/adb628f5d699bbe303955aa051da99f4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qtAnoDEEsPykGhYplrsssw--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/adb628f5d699bbe303955aa051da99f4"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-inc-adma-surpasses-172500702.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434516864","title":"ADMA Biologics Is Maintained at Strong Buy by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2434516864","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434516864?lang=en_us&edition=fundamental","pubTime":"2024-05-11 01:08","pubTimestamp":1715360880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADMA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 10, 2024 13:08 ET (17:08 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2434850807","title":"ADMA Biologics Up Over 24%, on Track for Highest Close Since December 2015 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2434850807","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434850807?lang=en_us&edition=fundamental","pubTime":"2024-05-10 22:40","pubTimestamp":1715352000,"startTime":"0","endTime":"0","summary":"ADMA Biologics, Inc.  is currently at $8.62, up $1.70 or 24.46%. --Would be highest close since Dec. 14, 2015, when it closed at $8.63. --On pace for largest percent increase since Nov. 10, 2022, when it rose 27.53%. --Currently up two consecutive days; up 25.73% over this period. --Down 31% from its all-time closing high of $12.50 on Nov. 6, 2014. --Up 104.38% from 52 weeks ago , when it closed at $4.22. --Up 180.03% from its 52-week closing low of $3.08 on Oct. 23, 2023. --Traded as high as $8.74; highest intraday level since April 5, 2016, when it hit $8.80. --Up 26.12% at today's intraday high; largest intraday percent increase since Nov. 10, 2022, when it rose as much as 29.15%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2434852514","title":"Novavax, Macrogenics, Biofrontera among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2434852514","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434852514?lang=en_us&edition=fundamental","pubTime":"2024-05-10 22:00","pubTimestamp":1715349627,"startTime":"0","endTime":"0","summary":"Gainers: Novavax  +134%. ITeos Therapeutics  +39%. Caredx  +27%. Adma Biologics  +21%. Sensus Healthcare  +19%.  Losers: Macrogenics  -71%. Progyny  -23%. Biofrontera  -16%. Protalix BioTherapeutics  -14%. Revance Therapeutics  -13%.  S&P 500 Health Care Sector +0.12% to 1670.59. Health Care Equipment & Services +0.12% to 1938.81. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.18% to 1369.27.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104635-novavax-macrogenics-biofrontera-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2434146856","title":"RNAZ, QBTS and WAVD are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2434146856","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434146856?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:02","pubTimestamp":1715346163,"startTime":"0","endTime":"0","summary":"Gainers: Novavax (NVAX) +108% surges as Sanofi COVID vaccine deal boosts outlook.  Aethlon Medical (AEMD) +42% Results From an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesi","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104576-rnaz-qbts-and-wavd-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2434855568","title":"ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2434855568","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434855568?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:32","pubTimestamp":1715344359,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38759083/adma-biologics-analysts-increase-their-forecasts-after-upbeat-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2434345878","title":"Strong Financial Performance and Growth Prospects Affirm Buy Rating for ADMA Biologics","url":"https://stock-news.laohu8.com/highlight/detail?id=2434345878","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434345878?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:46","pubTimestamp":1715338010,"startTime":"0","endTime":"0","summary":"Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on ADMA Biologics (ADMA – Research Report). The associated price target w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strong-financial-performance-and-growth-prospects-affirm-buy-rating-for-adma-biologics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strong-financial-performance-and-growth-prospects-affirm-buy-rating-for-adma-biologics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434027208","title":"Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2434027208","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2434027208?lang=en_us&edition=fundamental","pubTime":"2024-05-10 06:20","pubTimestamp":1715293207,"startTime":"0","endTime":"0","summary":"Adma Biologics  came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 60%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of 100%.Adma Biologics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $81.88 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 6.75%. This compares to year-ago revenues of $56.91 million. The company has topped consensus revenue estimates four times over the last four quarters.Adma Biologics shares have added about 51.8% since the beginning of the year versus the S&P 500's gain of 8.8%.While Adma Biologics has outperformed the market so far th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-surpasses-q1-222007412.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434040900","title":"ADMA Biologics Q1 2024 GAAP EPS $0.08 Beats $0.05 Estimate, Sales $81.875M Beat $77.275M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434040900","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434040900?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:28","pubTimestamp":1715286488,"startTime":"0","endTime":"0","summary":"ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.05 by 60 percent. This is a 366.67 percent increase over losses of $(0.03) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38745000/adma-biologics-q1-2024-gaap-eps-0-08-beats-0-05-estimate-sales-81-875m-beat-77-275m-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2434401480","title":"ADMA Biologics GAAP EPS of $0.08 beats by $0.02, revenue of $81.9M beats by $4.62M","url":"https://stock-news.laohu8.com/highlight/detail?id=2434401480","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434401480?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:23","pubTimestamp":1715286220,"startTime":"0","endTime":"0","summary":"ADMA Biologics press release : Q1 GAAP EPS of $0.08  beats by $0.02. Revenue of $81.9M   beats by $4.62M. FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million vs $333.78M consensus and $410 Million vs $389.98M consensus, Respectively FY 2024  Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than $110 Million FY 2025 Net Income Guidance Increased to More than $135 Million and Adjusted EBITDA Guidance Increased to More Than $160 Million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104089-adma-biologics-gaap-eps-of-0_08-beats-0_02-revenue-of-81_9m-beats-4_62m","is_publish_highlight":false,"gpt_icon":0},{"id":"2434404719","title":"ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2434404719","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2434404719?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:05","pubTimestamp":1715285100,"startTime":"0","endTime":"0","summary":"1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y. 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y. 1Q 2024 Adjusted EBITDA of $26.4 Million, a 970% Increase Y-o-Y. FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively. FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than $110 Million. FY 2025 Net Income Guidance Increased to More than $135 Million and Adjusted EBITDA Guidance Increased to More Than $160 Million. Strengthened Balance Sheet. Based on ADMA’s first quarter Adjusted EBITDA growth, the Company’s current net leverage ratio has organically improved to 0.85x. The Company anticipates continued strengthening of the balance sheet driven by forecasted Adjusted EBITDA growth and by what we believe will be a significant increase in free cash flow beginning in the second quarter of 2024","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/yyqKH5Vv8M4C82iGCJdVQw--~B/aD01MTU7dz0xNDgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/44fe490437b639c64991654da41d3431","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/yyqKH5Vv8M4C82iGCJdVQw--~B/aD01MTU7dz0xNDgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/44fe490437b639c64991654da41d3431"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-announces-first-quarter-200500354.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432962231","title":"Adma Biologics (ADMA) Rises Higher Than Market: Key Facts","url":"https://stock-news.laohu8.com/highlight/detail?id=2432962231","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432962231?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:45","pubTimestamp":1714686316,"startTime":"0","endTime":"0","summary":"Adma Biologics  closed the most recent trading day at $6.74, moving +1.05% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.91%. Elsewhere, the Dow gained 0.85%, while the tech-heavy Nasdaq added 1.51%.Coming into today, shares of the infectious disease drug developer had gained 5.04% in the past month. In that same time, the Medical sector lost 2.73%, while the S&P 500 lost 4.2%.The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release. The company is expected to report EPS of $0.05, up 266.67% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $76.7 million, reflecting a 34.77% rise from the equivalent quarter last year.Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-rises-higher-214516144.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.0454},{"period":"1month","weight":0.5248},{"period":"3month","weight":0.7443},{"period":"6month","weight":1.3199},{"period":"1year","weight":1.2797},{"period":"ytd","weight":1.0376}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.036203},{"month":2,"riseRate":0.5,"avgChangeRate":-0.013938},{"month":3,"riseRate":0.6,"avgChangeRate":0.097898},{"month":4,"riseRate":0.6,"avgChangeRate":0.007327},{"month":5,"riseRate":0.7,"avgChangeRate":0.070789},{"month":6,"riseRate":0.111111,"avgChangeRate":-0.078722},{"month":7,"riseRate":0.666667,"avgChangeRate":0.114663},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.032938},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.039779},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.036554},{"month":11,"riseRate":0.555556,"avgChangeRate":0.062096},{"month":12,"riseRate":0.4,"avgChangeRate":-0.05303}],"exchange":"NASDAQ","name":"ADMA Biologics","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ADMA Biologics,ADMA,ADMA Biologics股票,ADMA Biologics股票老虎,ADMA Biologics股票老虎国际,ADMA Biologics行情,ADMA Biologics股票行情,ADMA Biologics股价,ADMA Biologics股市,ADMA Biologics股票价格,ADMA Biologics股票交易,ADMA Biologics股票购买,ADMA Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction